The Growing Challenge of Diabetic Eye Disease

Diabetic eye disease, particularly diabetic retinopathy and diabetic macular edema, remains one of the most pressing causes of preventable blindness worldwide. With the global prevalence of diabetes continuing to rise, the burden of ocular complications has grown substantially. According to the National Eye Institute, diabetic retinopathy affects more than one in three people with diabetes, and it is the leading cause of new cases of blindness among adults aged 20 to 74 in the United States.

Traditional treatment paradigms have relied on laser photocoagulation, intravitreal anti-vascular endothelial growth factor (VEGF) injections, and corticosteroid therapies administered as monotherapy or in sequential steps. However, a significant subset of patients continues to experience disease progression, persistent edema, and vision loss despite these interventions. In response, clinicians are increasingly turning to combination approaches that target the multiple pathophysiological pathways driving diabetic eye disease. Triple therapy, which simultaneously employs laser, anti-VEGF, and corticosteroid modalities, has emerged as a powerful strategy for managing advanced and refractory cases.

This article examines real-world case studies demonstrating the effectiveness of triple therapy, explores the rationale behind combining these three distinct mechanisms of action, and discusses the clinical considerations for incorporating this approach into practice. The evidence suggests that triple therapy may offer superior anatomical and functional outcomes for carefully selected patients, particularly those with proliferative diabetic retinopathy complicated by macular edema.

Understanding the Components of Triple Therapy

Triple therapy for diabetic eye disease is defined by the coordinated use of three treatment modalities: laser photocoagulation, intravitreal anti-VEGF agents, and corticosteroid implants or injections. Each component addresses a different aspect of diabetic retinal pathology, and their combined use is intended to produce synergistic effects that no single agent can achieve alone.

Laser Photocoagulation

Laser therapy has been a cornerstone of diabetic retinopathy management for decades. Panretinal photocoagulation (PRP) is used to ablate ischemic retinal tissue in proliferative diabetic retinopathy, reducing the production of VEGF and other angiogenic factors. Focal or grid laser is applied to treat specific areas of vascular leakage responsible for diabetic macular edema. While laser monotherapy can stabilize vision and reduce the risk of severe vision loss, it often does not improve visual acuity and can cause collateral damage to retinal tissue, including reductions in peripheral vision and night vision.

Intravitreal Anti-VEGF Agents

The introduction of anti-VEGF therapies transformed the management of diabetic retinopathy and macular edema. Agents such as ranibizumab, aflibercept, and bevacizumab directly neutralize VEGF, a key driver of vascular permeability and neovascularization. Anti-VEGF injections can rapidly reduce macular edema, improve visual acuity, and induce regression of retinal neovascularization. However, frequent injections are required to maintain effects, and some patients exhibit an incomplete or waning response over time. The burden of repeated injections also presents logistical and financial challenges.

Corticosteroid Implants and Injections

Corticosteroids exert broad anti-inflammatory and anti-edematous effects by stabilizing endothelial tight junctions, reducing inflammatory cytokine production, and inhibiting leukocyte adhesion. The dexamethasone intravitreal implant (Ozurdex) and the fluocinolone acetonide implant (Iluvien) provide sustained release of corticosteroid over several months, offering a durable treatment option for chronic diabetic macular edema. Corticosteroids are particularly useful in patients who are poor responders to anti-VEGF therapy or who have a significant inflammatory component to their disease.

Mechanisms of Synergy in Triple Therapy

The rationale for triple therapy lies in the complementary mechanisms of action of its three components. Laser photocoagulation reduces the overall burden of ischemic retina, thereby decreasing the stimulus for VEGF production. Anti-VEGF agents neutralize any remaining VEGF that has already been produced, preventing neovascularization and vascular leakage. Corticosteroids address the inflammatory milieu that contributes to blood-retinal barrier breakdown and can potentiate the effects of anti-VEGF therapy by reducing inflammatory cytokines that upregulate VEGF expression.

By targeting multiple pathways simultaneously, triple therapy may achieve more complete and durable control of disease activity. This is particularly relevant in advanced cases where a single pathway is not the sole driver of pathology. Clinical evidence suggests that combination therapy can lead to greater reductions in central retinal thickness, more sustained improvements in visual acuity, and a lower need for repeated retreatments compared to monotherapy or even dual therapy.

Case Study 1: Advanced Proliferative Diabetic Retinopathy with Refractory Macular Edema

A 58-year-old man with a 20-year history of type 2 diabetes and hypertension presented with progressive vision loss in his right eye over the preceding six months. His hemoglobin A1c was 8.9%, and his blood pressure was 145/90 mmHg despite oral medications. On examination, his best-corrected visual acuity (BCVA) was 20/80 in the right eye and 20/40 in the left eye. Fundus examination revealed severe proliferative diabetic retinopathy with active neovascularization of the disc and vitreous hemorrhage in the right eye, along with clinically significant macular edema involving the fovea. Optical coherence tomography (OCT) showed a central subfield thickness (CST) of 485 micrometers in the right eye.

The patient had previously received three monthly anti-VEGF injections with only partial improvement in macular edema and no regression of neovascularization. Given the advanced nature of the disease and the incomplete response to anti-VEGF monotherapy, the decision was made to proceed with triple therapy.

The treatment protocol was initiated with panretinal photocoagulation delivered over two sessions to ablate ischemic retina. One week after the final laser session, the patient received an intravitreal injection of aflibercept (2 mg) and a dexamethasone intravitreal implant (0.7 mg) in the same operative session. Post-injection intraocular pressure was monitored and remained within normal limits.

Follow-up examinations were conducted at one, three, and six months. At the one-month visit, BCVA had improved to 20/60, and CST had decreased to 320 micrometers. The vitreous hemorrhage had cleared, and neovascularization appeared regressed. By three months, BCVA improved further to 20/40, and CST was 275 micrometers. At six months, visual acuity stabilized at 20/30, and OCT showed near-complete resolution of macular edema with a CST of 240 micrometers. No significant adverse events were observed, though the patient did develop a transient elevation of intraocular pressure to 24 mmHg at the one-month visit, which resolved with topical brimonidine therapy. No cataract progression was noted during the follow-up period.

This case illustrates that triple therapy can salvage vision in patients with advanced proliferative retinopathy and macular edema that has proven resistant to anti-VEGF monotherapy. The combination of laser to reduce ischemic drive, anti-VEGF to neutralize circulating VEGF, and corticosteroid to suppress inflammation achieved a more robust and durable response than any single modality had provided.

Case Study 2: Persistent Diabetic Macular Edema in a Patient with Prior Laser and Anti-VEGF Therapy

A 65-year-old woman with type 2 diabetes diagnosed 15 years earlier presented with bilateral diabetic macular edema. She had undergone focal laser therapy two years prior and had received eight anti-VEGF injections over the following 18 months. Despite this treatment burden, her vision had not improved, and she continued to experience central vision distortion and difficulty reading. Her BCVA was 20/50 in the right eye and 20/60 in the left eye. OCT revealed CST of 420 micrometers in the right eye and 450 micrometers in the left eye, with evidence of subretinal fluid and intraretinal cysts. Fluorescein angiography showed diffuse leakage with areas of capillary nonperfusion.

The patient was considered a candidate for triple therapy given the persistence of edema despite aggressive anti-VEGF treatment and prior laser. The treatment plan for the right eye included focal/grid laser to areas of leakage identified on angiography, followed by intravitreal bevacizumab (1.25 mg) and a dexamethasone implant administered one week later.

At the three-month follow-up, BCVA in the right eye had improved to 20/30, and CST decreased to 310 micrometers. The subretinal fluid and intraretinal cysts resolved. The patient reported meaningful improvement in visual function, including the ability to read newspaper print without magnification. At six months, BCVA remained stable at 20/25, and CST was 280 micrometers. No recurrence of edema was observed. The left eye was subsequently treated with the same protocol and achieved comparable results.

No serious adverse events occurred during the follow-up period. Intraocular pressure remained within normal limits, and no cataract progression was noted. The patient required no additional anti-VEGF injections during the six-month follow-up, representing a significant reduction in treatment burden compared to her previous regimen of injections every six to eight weeks.

This case demonstrates that triple therapy can provide benefit even in eyes with chronic, treatment-resistant macular edema. The addition of corticosteroid therapy appeared to address an inflammatory component that was not adequately controlled by anti-VEGF alone, while laser reduced the ongoing stimulus for edema formation.

Case Study 3: High-Risk Proliferative Diabetic Retinopathy with Bilateral Disease

A 52-year-old man with poorly controlled type 2 diabetes (HbA1c 10.2%) presented with acute vision loss in his left eye due to vitreous hemorrhage. His right eye had been previously treated with PRP and had stable vision of 20/30. Examination of the left eye revealed dense vitreous hemorrhage obscuring view of the posterior pole, with B-scan ultrasound showing a detached posterior hyaloid but no retinal detachment. BCVA in the left eye was hand motion. The right eye showed regressed neovascularization with stable macular thickness.

Given the high-risk nature of the left eye and the patient's poor systemic control, triple therapy was considered to achieve rapid regression of neovascularization and prevent recurrent hemorrhage. The patient underwent PRP laser in the left eye targeting peripheral ischemic retina visible through the hemorrhage. One week later, he received an intravitreal injection of aflibercept (2 mg) and a dexamethasone implant.

At the two-week follow-up, the vitreous hemorrhage had cleared significantly, and fundus examination showed regressed neovascularization. BCVA improved to 20/80. By three months, BCVA was 20/40, and OCT showed normal macular thickness. The patient maintained stable vision at six-month follow-up with no recurrent hemorrhage. A planned second PRP session was deferred, as the neovascularization had regressed completely.

This case highlights the potential of triple therapy to induce rapid and complete regression of active neovascularization in the setting of acute vitreous hemorrhage. The combination of laser, anti-VEGF, and corticosteroid may accelerate clearance of hemorrhage, reduce the risk of recurrent bleeding, and reduce the need for additional laser sessions.

Evidence from the Broader Clinical Literature

While the case studies above illustrate the potential of triple therapy in individual patients, they are consistent with findings from a growing body of clinical research. Several prospective studies and meta-analyses have reported that combination therapy with laser, anti-VEGF, and corticosteroid produces greater improvements in visual acuity and central retinal thickness compared to laser alone or anti-VEGF alone in patients with diabetic macular edema. A large meta-analysis published in JAMA Ophthalmology found that combination therapy was associated with a mean gain of 15 or more letters in a significantly higher proportion of patients after 12 months compared with laser monotherapy.

The Diabetic Retinopathy Clinical Research Network (DRCR.net) has conducted multiple trials evaluating combination approaches, including protocols T and U, which have informed the development of standardized treatment algorithms. These studies have shown that while anti-VEGF monotherapy remains the standard first-line treatment for center-involving diabetic macular edema, the addition of corticosteroid therapy in patients who do not achieve adequate response after 3-6 months of anti-VEGF monotherapy can lead to further improvements in anatomical and functional outcomes.

Additionally, studies specifically evaluating triple therapy as an upfront approach in patients with proliferative diabetic retinopathy complicated by macular edema have demonstrated high rates of disease stabilization and vision improvement, with some data suggesting a reduced need for future vitrectomy. The American Academy of Ophthalmology has noted that combination strategies continue to evolve, and that individualized treatment plans based on patient-specific factors such as inflammation status, lens clarity, and glaucoma risk are essential.

Patient Selection: Identifying Candidates for Triple Therapy

Triple therapy is not appropriate for all patients with diabetic eye disease. Careful patient selection is critical to maximizing benefits while minimizing risks. The most suitable candidates typically exhibit one or more of the following characteristics:

  • Persistent diabetic macular edema despite a minimum of three to six anti-VEGF injections. Patients who show a partial but incomplete response, or who require very frequent injections to maintain control, may benefit from the addition of corticosteroid and laser therapy.
  • Proliferative diabetic retinopathy with concurrent, treatment-resistant macular edema. In these patients, the combined approach can simultaneously address neovascularization and edema, potentially reducing the need for separate treatment episodes.
  • Significant inflammatory component to their disease. Patients with high levels of inflammatory markers on OCT or clinical examination, or those with a history of uveitis or other inflammatory conditions, may respond well to corticosteroid therapy.
  • High-risk features such as vitreous hemorrhage or active neovascularization. Triple therapy may induce more rapid regression of neovascularization and reduce the risk of bleeding compared to monotherapy.
  • Inability to adhere to frequent injection schedules. The sustained effect of the dexamethasone or fluocinolone implant may reduce visit frequency for patients with transportation or compliance challenges.

Patients with significant glaucoma, ocular hypertension, or a history of steroid-induced intraocular pressure elevation may not be suitable candidates for corticosteroid therapy, or may require careful monitoring and prophylactic intraocular pressure-lowering treatment. Similarly, patients with advanced cataracts may be at risk for progression, and those with significant media opacity may not be good candidates for laser therapy.

Safety Profile and Managing Adverse Effects

Triple therapy is generally well tolerated, but it carries potential risks that clinicians must anticipate and manage. The most common adverse effects associated with the individual components include intraocular pressure elevation (corticosteroid-related), cataract progression (corticosteroid-related), endophthalmitis (injection-related), retinal detachment (injection-related), and laser-related complications such as visual field loss, night vision disturbances, and macular burns.

In the three case studies presented, no serious adverse events occurred, but transient intraocular pressure elevation requiring topical therapy was observed in one patient. This highlights the need for routine intraocular pressure monitoring in all patients receiving corticosteroid implants, particularly in the first one to three months following implantation. For patients with pre-existing glaucoma, the use of a fluocinolone acetonide implant (Iluvien) may be associated with a lower risk of intraocular pressure elevation compared to dexamethasone, though data are still emerging.

Cataract progression is a well-known side effect of corticosteroid therapy, particularly with repeated or sustained-release formulations. In patients who are phakic, the risk of needing cataract surgery within one to two years of initiating corticosteroid therapy is approximately 20-30%. This risk must be weighed against the potential benefits of improved vision from edema resolution. Patients should be counseled about this possibility before treatment.

Infectious endophthalmitis and sterile intraocular inflammation are rare but serious complications of any intravitreal injection. Strict sterile technique and the use of povidone-iodine antisepsis are essential. Patients should be educated about the signs of endophthalmitis and instructed to report any pain, redness, or vision loss immediately.

Practical Considerations for Implementing Triple Therapy in Clinical Practice

Adopting triple therapy requires careful planning and coordination within the clinical practice. Key considerations include treatment sequencing, medication selection, follow-up scheduling, and patient education.

Regarding sequencing, most protocols perform laser photocoagulation first, allowing ischemic retinal tissue to be treated and the stimulus for VEGF production to be reduced. Anti-VEGF injection and corticosteroid implantation can be performed in the same session or separated by one to two weeks. There is no clear evidence that one approach is superior to the other, and the choice may depend on practitioner preference and logistical considerations. Performing both injections in the same session minimizes the number of visits for the patient but also introduces a slightly higher theoretical risk of endophthalmitis due to two injections.

Medication selection should be individualized. For anti-VEGF therapy, aflibercept may offer advantages in patients with high VEGF levels or those who have shown a suboptimal response to ranibizumab or bevacizumab. For corticosteroid therapy, the dexamethasone implant provides a three- to four-month duration of effect and is suitable for initial treatment, while the fluocinolone implant offers a three-year duration and is reserved for chronic, non-infectious uveitis or diabetic macular edema that has been previously treated with corticosteroids.

Follow-up schedules should be tailored to the patient's clinical status. A typical schedule includes visits at one month post-treatment to assess intraocular pressure and early treatment response, then three-month intervals for the duration of the implant effect. Additional visits may be needed if intraocular pressure elevation occurs or if disease activity recurs.

Patient education is perhaps the most important component of successful triple therapy. Patients must understand the rationale for combining three treatments, the expected timeline for improvement, and the need for meticulous follow-up. Written and verbal instructions regarding signs of adverse effects, as well as the importance of systemic diabetes and blood pressure control, should be provided.

The Role of Systemic Risk Factor Management

No discussion of diabetic eye disease treatment is complete without emphasizing the critical role of systemic risk factor management. Triple therapy can achieve excellent ocular outcomes, but these gains are at risk of being undermined by poorly controlled diabetes, hypertension, and dyslipidemia. As the Centers for Disease Control and Prevention highlights, optimizing glycemic control, blood pressure, and lipid levels can slow the progression of retinopathy and reduce the risk of vision loss by up to 50%.

In the case studies presented, the first patient had suboptimal glycemic and blood pressure control at baseline, and his HbA1c remained elevated at follow-up despite medication adjustment. While triple therapy was effective in improving his ocular condition, long-term disease stability will depend on improvements in his systemic health. Coordinated care with the patient's primary care physician or endocrinologist is essential to achieving the best overall outcomes.

Smoking cessation, dietary modification, and regular exercise are also important components of a comprehensive treatment plan. Patients should be counseled about the impact of lifestyle choices on their eye health and encouraged to set goals for improvement.

Future Directions and Unanswered Questions

Triple therapy for diabetic eye disease is a relatively new and evolving treatment paradigm, and several important questions remain unanswered. Long-term safety data beyond one year are still limited, particularly regarding the cumulative effects of repeated corticosteroid implants on cataract formation, intraocular pressure, and the risk of glaucoma. The optimal timing and frequency of triple therapy cycles have not been established, and the role of maintenance therapy versus as-needed retreatment is an area of active investigation.

Randomized controlled trials comparing triple therapy head-to-head with monotherapy and dual therapy are needed to establish standardized protocols and to determine which patient populations derive the greatest benefit. The DRCR.net has initiated studies evaluating combination strategies, and the results of these trials will inform future clinical guidelines.

Advances in imaging technology may also help refine patient selection for triple therapy. OCT angiography can identify areas of capillary nonperfusion and neovascularization with high resolution, potentially enabling more targeted laser treatment. Inflammatory biomarkers, such as aqueous humor cytokine levels measured at the time of injection, may allow clinicians to identify patients who are most likely to benefit from corticosteroid therapy.

Artificial intelligence and machine learning algorithms are being developed to predict treatment response based on baseline clinical and imaging data. These tools could enable personalized treatment plans that select the optimal combination and sequencing of laser, anti-VEGF, and corticosteroid therapy for each individual patient.

Finally, the development of new therapeutic agents targeting additional pathways, such as angiopoietin-2 and Tie2 receptor agonists, may further expand the available options for combination therapy. The future of diabetic eye disease management will likely involve increasingly sophisticated and personalized treatment algorithms that incorporate multiple agents targeting distinct molecular pathways.

Conclusion

Diabetic eye disease remains a formidable clinical challenge, but the advent of triple therapy combining laser photocoagulation, intravitreal anti-VEGF agents, and corticosteroid implants offers new hope for patients with advanced or treatment-resistant disease. The case studies presented in this article demonstrate that this combination approach can achieve significant improvements in visual acuity and anatomical outcomes in patients who have not responded adequately to conventional therapies. By addressing the multiple pathophysiological pathways driving disease progression, triple therapy provides a comprehensive treatment strategy that can stabilize vision, reduce edema, and regress neovascularization.

Successful implementation of triple therapy requires careful patient selection, meticulous attention to safety monitoring, and a coordinated approach that includes systemic risk factor optimization. While further research is needed to refine protocols and establish long-term safety data, the existing evidence supports the use of triple therapy as a valuable option in the armamentarium of clinicians managing diabetic eye disease. As the field continues to evolve, combination approaches like triple therapy will likely become an integral component of personalized treatment plans, helping to reduce the burden of vision loss from this increasingly prevalent condition.

Clinicians who treat patients with diabetic retinopathy and macular edema should consider triple therapy in appropriate candidates and remain informed about the evolving evidence base. For patients facing the prospect of progressive vision loss despite aggressive treatment, triple therapy may represent the difference between disease progression and lasting visual preservation.